Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hard-Core Computing To Drive Microbiome-based R&D

Executive Summary

Israel’s RondinX is analyzing the microbiome with specific algorithms in order to develop new therapeutic approaches to disease.

You may also be interested in...



Deal Watch: Boehringer's Busy End Of Year Includes Deals With Roche, Autifony

The German pharma options potassium channel modulator technology from Autifony and partners with Roche on immunological approaches to irritable bowel syndrome. Roche unveils discovery pacts with Confo and DiCE.

Deal Watch: J.P. Morgan Brings Continued Brisk Pace Of Transactions

Allergan strikes a pair of deals for gastrointestinal and CNS candidates, while Amgen expands its reach in bispecific antibodies via a partnership with Immatics.

Microbiotica: Wellcome Spin-Out Exploits Unique Microbe Collection

Emerging Company Profile: Microbiotica, a UK biotech spin-out from the Wellcome Trust Sanger Institute announced late last year, says it has unique capabilities in culturing and sequencing the human bacterial microbiome that will be of use to develop bacterial mixes for therapeutic use.

Topics

Related Companies

UsernamePublicRestriction

Register

GB150366

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel